Abstract

This article explores the dynamic advancements in Multiple Myeloma (MM) therapy, emphasizing the transformative shift towards precision medicine. MM, a complex and currently incurable blood cancer, has witnessed remarkable progress in recent years. The evolving treatment landscape reflects a paradigm shift, focusing on tailoring interventions based on the unique genetic and molecular characteristics of individual patients. Novel drug classes, including proteasome inhibitors and immunomodulatory drugs, alongside groundbreaking immunotherapies like monoclonal antibodies and CAR T-cell therapy, have redefined the therapeutic arsenal against MM. Precision medicine, guided by comprehensive genomic profiling, stands as a beacon of hope, offering a personalized approach that maximizes treatment efficacy while minimizing side effects. The article navigates through these advancements, delving into the promise of precision medicine and the challenges that lie ahead, ultimately envisioning a future where tailored treatments revolutionize outcomes for individuals grappling with multiple myeloma.